Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator

BMC Cancer

Philip Vlaicu⁴  Philipp Mertins²  Thomas Mayr⁴  Peter Widschwendter³  Beyhan Ataseven¹  Bernhard Högel¹  Wolfgang Eiermann¹  Pjotr Knyazev⁴  Axel Ullrich⁴ 

[1] Department of Gynecology and Obstetrics, Red Cross Hospital, Munich 80637, Germany

[2] Current address: Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

[3] Current address: University Hospital for Women, University of Tuebingen, Tuebingen 72076, Germany

[4] Department of Molecular Biology, Max Planck Institute of Biochemistry, Martinsried 82152, Germany

关键词: Progression;    Marker;    STAT3;    EGFR;    Patient;    Carcinoma;    Breast;    Monocyte;    Macrophage;    TAM;   

Others  :  1079794
DOI  :  10.1186/1471-2407-13-197

 received in 2012-12-29, accepted in 2013-04-08,  发布年份 2013

【 摘 要 】

Background

Tumor-associated macrophages (TAM) promote malignant progression, yet the repertoire of oncogenic factors secreted by TAM has not been clearly defined. We sought to analyze which EGFR- and STAT3-activating factors are secreted by monocytes/macrophages exposed to tumor cell-secreted factors.

Methods

Following exposure of primary human monocytes and macrophages to supernatants of a variety of tumor cell lines, we have analyzed transcript and secreted protein levels of EGFR family ligands and of STAT3 activators. To validate our findings, we have analyzed TAM infiltration levels, systemic and local protein levels as well as clinical data of primary breast cancer patients.

Results

Primary human monocytes and macrophages respond to tumor cell-derived factors by secreting EGFR- and STAT3-activating ligands, thus inducing two important oncogenic pathways in carcinoma cells. Tumor cell-secreted factors trigger two stereotype secretory profiles in peripheral blood monocytes and differentiated macrophages: monocytes secrete epiregulin (EREG) and oncostatin-M (OSM), while macrophages secrete heparin-binding EGF-like growth factor (HB-EGF) and OSM. HB-EGF and OSM cooperatively induce tumor cell chemotaxis. HB-EGF and OSM are co-expressed by TAM in breast carcinoma patients, and plasma levels of both ligands correlate strongly. Elevated HB-EGF levels accompany TAM infiltration, tumor growth and dissemination in patients with invasive disease.

Conclusions

Our work identifies systemic markers for TAM involvement in cancer progression, with the potential to be developed into molecular targets in cancer therapy.

【 授权许可】

   
2013 Vlaicu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Politi K, Fan PD, Shen R, Zakowski M, Varmus H: Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 2010, 3(1–2):111-119.
• [2]Johansson M, Denardo DG, Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
• [3]Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-265.
• [4]Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193(6):727-740.
• [5]Martin P, Leibovich SJ: Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005, 15(11):599-607.
• [6]Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78.
• [7]De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8(3):211-226.
• [8]Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41-51.
• [9]Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354.
• [10]O’Sullivan C, Lewis CE, Harris AL, McGee JO: Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993, 342(8864):148-149.
• [11]Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000, 190(4):430-436.
• [12]Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J: A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004, 64(19):7022-7029.
• [13]Mantovani A, Bottazzi B, Sozzani S, Peri G, Allavena P, Dong QG, Vecchi A, Colotta F: Cytokine regulation of monocyte recruitment. Arch Immunol Ther Exp (Warsz) 1995, 43(2):149-152.
• [14]Gschwind A, Prenzel N, Ullrich A: Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002, 62(21):6329-6336.
• [15]Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251(4996):936-939.
• [16]Nishi E, Klagsbrun M: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004, 22(4):253-260.
• [17]Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004, 64(16):5720-5727.
• [18]Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005, 11(13):4783-4792.
• [19]Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E: A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61(16):6227-6233.
• [20]Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ: Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci USA 1986, 83(24):9739-9743.
• [21]Zhang F, Li C, Halfter H, Liu J: Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003, 22(6):894-905.
• [22]Boylan M, van den Berg HW, Lynch M: The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 1998, 9(2):205-211.
• [23]Martinez-Lacaci I, Kannan S, De Santis M, Bianco C, Kim N, Wallace-Jones B, Ebert AD, Wechselberger C, Salomon DS: RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. International journal of cancer Journal international du cancer 2000, 88(1):44-52.
• [24]Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S: A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008, 122(6):1324-1332.
• [25]Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C: Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006, 38(12):1386-1396.
• [26]Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475(7355):222-225.
• [27]Yu H, Jove R: The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004, 4(2):97-105.
• [28]Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, Wongkham S: Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 2010, 161(3):471-479.
• [29]Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
• [30]Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA: Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459(7249):1005-1009.
• [31]Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, Nesland JM: The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol 2002, 10(2):91-99.
• [32]Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N: Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001, 67(1):81-85.
• [33]Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 2010, 9(1):273. BioMed Central Full Text
• [34]Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA: Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010, 184(7):3964-3977.
• [35]Goren I, Kampfer H, Muller E, Schiefelbein D, Pfeilschifter J, Frank S: Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetes-impaired wounds. J Invest Dermatol 2006, 126(3):628-637.
• [36]Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P, Abraham J, Klagsbrun M: Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993, 90(9):3889-3893.